Compare PLETHICO PHARMA with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA FDC LTD. PLETHICO PHARMA/
FDC LTD.
 
P/E (TTM) x -1.1 17.5 - View Chart
P/BV x 0.0 2.4 0.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   FDC LTD.
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
FDC LTD.
Mar-18
PLETHICO PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs395319 123.8%   
Low Rs31164 19.1%   
Sales per share (Unadj.) Rs604.461.6 980.5%  
Earnings per share (Unadj.) Rs32.59.9 326.5%  
Cash flow per share (Unadj.) Rs51.312.0 429.0%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.673.2 647.2%  
Shares outstanding (eoy) m34.08174.40 19.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.43.9 9.0%   
Avg P/E ratio x6.624.3 27.0%  
P/CF ratio (eoy) x4.220.2 20.6%  
Price / Book Value ratio x0.53.3 13.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,26242,118 17.2%   
No. of employees `000NA5.5 0.0%   
Total wages/salary Rs m1,5962,167 73.7%   
Avg. sales/employee Rs ThNM1,943.7-  
Avg. wages/employee Rs ThNM391.7-  
Avg. net profit/employee Rs ThNM313.7-  
INCOME DATA
Net Sales Rs m20,59810,751 191.6%  
Other income Rs m386510 75.8%   
Total revenues Rs m20,98411,260 186.4%   
Gross profit Rs m2,8182,267 124.3%  
Depreciation Rs m642351 182.8%   
Interest Rs m1,59314 11,380.0%   
Profit before tax Rs m9692,411 40.2%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138671 -20.6%   
Profit after tax Rs m1,1071,735 63.8%  
Gross profit margin %13.721.1 64.9%  
Effective tax rate %-14.327.8 -51.3%   
Net profit margin %5.416.1 33.3%  
BALANCE SHEET DATA
Current assets Rs m18,8777,213 261.7%   
Current liabilities Rs m11,8962,104 565.5%   
Net working cap to sales %33.947.5 71.3%  
Current ratio x1.63.4 46.3%  
Inventory Days Days3654 65.9%  
Debtors Days Days19828 713.5%  
Net fixed assets Rs m9,8616,865 143.6%   
Share capital Rs m341175 194.5%   
"Free" reserves Rs m12,33112,586 98.0%   
Net worth Rs m16,13912,761 126.5%   
Long term debt Rs m4,7066 78,430.0%   
Total assets Rs m33,14615,041 220.4%  
Interest coverage x1.6173.2 0.9%   
Debt to equity ratio x0.30 62,016.1%  
Sales to assets ratio x0.60.7 86.9%   
Return on assets %8.111.6 70.1%  
Return on equity %6.913.6 50.4%  
Return on capital %12.319.0 64.8%  
Exports to sales %21.412.3 173.2%   
Imports to sales %15.20-   
Exports (fob) Rs m4,4021,327 331.8%   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,4021,889 233.1%   
Fx outflow Rs m3,1840-   
Net fx Rs m1,2191,889 64.5%   
CASH FLOW
From Operations Rs m2,4371,498 162.7%  
From Investments Rs m-6,265201 -3,115.2%  
From Financial Activity Rs m2,490-1,694 -147.0%  
Net Cashflow Rs m-1,33710 -12,982.1%  

Share Holding

Indian Promoters % 82.7 68.9 120.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 4.7 91.5%  
FIIs % 5.5 7.5 73.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 19.0 39.5%  
Shareholders   10,665 23,730 44.9%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

FDC LTD. Announces Quarterly Results (3QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Feb 15, 2019 | Updated on Feb 15, 2019

For the quarter ended December 2018, FDC LTD. has posted a net profit of Rs 437 m (up 2.5% YoY). Sales on the other hand came in at Rs 3 bn (up 1.4% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (2QFY19); Net Profit Down 33.6% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, FDC LTD. has posted a net profit of Rs 431 m (down 33.6% YoY). Sales on the other hand came in at Rs 3 bn (down 12.0% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - UNICHEM LAB COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS